Mepolizumab

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting.

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster presented at the CHEST Annual Meeting.

Patients with severe asthma and small airways disease did not respond as well to omalizumab treatment, according to a poster presented at the European Respiratory Society International Congress.

Mepolizumab and benralizumab had similar safety profiles for patients with severe eosinophilic asthma despite their different mechanisms, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — Breath profile clusters can predict positive response to anti-IL5 or anti-IL5R alpha asthma treatment 1 month after initiation, according to an abstract presented at the American Thoracic Society International Conference.

SAN DIEGO — The relative expressions of three genes associated with the airway predicted mepolizumab response among urban children with asthma, according to a study presented at the American Thoracic Society International Conference.

SAN DIEGO — Rates of serious adverse events for patients on mepolizumab were comparable with those using placebo across 7,429 patient-years of exposure, according to a presentation at the American Thoracic Society International Conference.

Biologics designed to counter type 2 inflammation reduced asthma exacerbations in real world settings, with dupilumab having the most impact, according to a study in he Journal of Allergy and Clinical Immunology: In Practice.

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The New England Journal of Medicine.